Health Canada Database Lists Trimbow as Marketed in Canada

Health Canada’s Drug Product Database (DPD) now lists Trimbow as Marketed, with a current-status date of September 24, 2026. The prescription inhaler combines beclomethasone dipropionate, glycopyrronium and formoterol in a pressurized metered-dose device. The database entry is a useful signal that the sponsor has reported the product as marketed in Canada, but it should not be mistaken for a new regulatory authorization: Health Canada authorized Trimbow on May 16, 2025.

What the status change does—and does not—tell us

The DPD records a Canadian market status and a drug identification number (DIN 02557592). Its “original market date” and “current status date” both show September 24, 2026. These fields help clinicians and dispensaries establish that a product has entered the market-recording system. They do not show whether a particular wholesaler has stock, whether every pharmacy can order it, what the patient will pay, or whether a public drug plan covers it. Pharmacists should confirm supply and coverage through their usual provincial and wholesaler channels rather than infer access from the database alone.

The distinction matters because the product monograph predates the market-status date by more than a year. The monograph was authorized in May 2025, and the DPD’s more recent entry reflects a different step in the product’s lifecycle. Coverage decisions and formulary listings are separate processes; no coverage conclusion can be drawn from this DPD entry.

Its authorized role is maintenance treatment for COPD

Trimbow is a three-in-one inhaled combination: an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA) and a long-acting beta₂-agonist (LABA). Health Canada’s monograph indicates it for adults with chronic obstructive pulmonary disease (COPD), including chronic bronchitis or emphysema, whose condition is not adequately treated by an ICS/LABA combination or a LABA/LAMA combination. It is intended for long-term maintenance of airflow obstruction and to reduce COPD exacerbations in patients with an exacerbation history.

This is not a general-purpose inhaler for any respiratory diagnosis. The Canadian monograph does not authorize Trimbow for asthma or for people under 18. It is also not a rescue medicine for sudden breathlessness or an acute COPD episode. Patients need an appropriate short-acting bronchodilator for acute symptoms and should know which device to use when symptoms suddenly worsen. A change in maintenance therapy should be made by the prescriber in the context of the patient’s history, symptoms, exacerbations and existing treatment.

Practical counselling points

Because the device contains both a LAMA and a LABA, the monograph warns against combining it with other medicines containing either class unless a prescriber has specifically reviewed the regimen; duplicate long-acting bronchodilators can raise the risk of excessive exposure. Patients should use it regularly as prescribed, even when they feel well, and should not increase the dose or frequency on their own. The monograph’s recommended regimen is two inhalations twice daily; any patient-specific directions should be confirmed against the current prescription and product information.

Device technique deserves attention at initiation and during follow-up. The monograph says a health professional should demonstrate correct inhaler use and periodically check technique. Pharmacists can ask patients to show how they prepare and use the inhaler, then correct issues with coordination, inhalation or device handling using the manufacturer’s instructions. After each prescribed dose, patients should rinse the mouth with water and spit it out rather than swallow it. This helps reduce the chance of local corticosteroid effects such as oral thrush.

Patients should also be reminded not to stop the maintenance inhaler without medical advice. If control deteriorates, the reliever is less effective, or reliever use increases, the monograph calls for prompt reassessment of the patient and treatment plan. Those signs should not be managed by simply taking extra Trimbow.

What pharmacists can verify now

The immediate practice question is not whether Trimbow has a new indication—it does not—but whether it is available through local supply channels and relevant to a patient who meets the approved COPD criteria. The DPD record provides the DIN and current status; the Health Canada monograph remains the source for authorized use, warnings and administration. Before dispensing, confirm the product, DIN, prescribed directions and actual availability, and check the applicable provincial or private coverage source. For patients already using other long-acting inhalers, reconcile the full regimen and make sure they understand which inhaler is for maintenance and which is for quick relief.

This report summarizes Health Canada product information for professional awareness; it is not an individual treatment recommendation.

Primary sources: Health Canada Drug Product Database: Trimbow, DIN 02557592; Health Canada-authorized Canadian Product Monograph.